The Moderna logo is seen at the Moderna campus in Norwood, Massachusetts on on December 2, 2020, where the biotechnology company is mass producing its Covid-19 vaccine. Moderna announced Wednesday ...

A vial and syringe are seen in front of a displayed Moderna logo in this illustration taken Jan 11 ... Moderna has already registered a biotech company in Minhang district and established its Chinese ...

First, let's back up a bit and take a look at the Moderna story, from the glory days of a few years ago to its troubles today ...

The Department of Health and Human Services (HHS) has axed a $590 million contract with Moderna, raising doubts about how the biotech will fund late-phase development of a pandemic bird flu vaccine.

Allison DeAngelis is the East Coast biotech and venture capital reporter ... and the cancellation of a $600 million contract with Moderna to develop, test and license vaccines for subtypes of ...

Moderna has announced the FDA approval of a new, lower-dose messenger RNA (mRNA) vaccine against COVID-19, called mNEXSPIKE (mRNA-1283) (1). The product joins Moderna’s original COVID vaccine, ...

But for investors who don't mind some volatility and plan on holding on to the stock for at least five years, Moderna makes an exciting biotech buy right now. If the company even partially reaches ...

The talks are the first hint that Merck is returning to the negotiating table a year after buying EyeBio in its last multibillion-dollar biotech deal. Its shares have fallen 39% over the past year ...

Now the biotech is caught in the crossfire of Trump 2.0 as vaccine-making comes under fire. In the latest setback for Moderna, the Food and Drug Administration on Friday approved its next ...

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...